Idexx Laboratories Inc Revenue Growth Rates (IDXX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Idexx Laboratories Inc  (NASDAQ: IDXX)
 

IDXX's Revenue Growth by Quarter and Year

Idexx Laboratories Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IDXX/growth
https://api.csimarket.com/api/v1/companies/IDXX/fundamentals
https://api.csimarket.com/api/v1/companies/IDXX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IDXX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,214.24
2nd Quarter June 1,216.59
1st Quarter March 1,140.74
FY 3,571.57

IDXXs Annual Revenue
Idexx Laboratories Inc's Revenue in the fiscal year 2025 $ 4,303.58 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2024 $ 3,896.93 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2023 $ 3,659.97 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2022 $ 3,367.32 millions
Idexx Laboratories Inc's Revenue in the fiscal year 2021 $ 3,215.36 millions




IDXX Revenue third quarter 2026 Y/Y Growth Comment
Idexx Laboratories Inc achieved in the third quarter 2026, above Company average Revenue improvement of 9.95% year on year, to $ 1,214.24 millions.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Idexx Laboratories Inc' s Revenue increase of 9.95% ranks overall at the positon no. 1761 in the third quarter 2026.


IDXX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.95 %
2nd Quarter June 9.73 %
1st Quarter March 14.26 %
FY   -

Financial Statements
Idexx Laboratories Inc's third quarter 2026 Revenue $ 1,214.24 millions IDXX's Income Statement
Idexx Laboratories Inc's third quarter 2025 Revenue $ 1,104.35 millions Quarterly IDXX's Income Statement


IDXX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.19 %
2nd Quarter June 6.65 %
1st Quarter March 4.45 %
FY (Year on Year)   -


Back to IDXX Growth rate Comparisons >> Back to IDXX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #278
Overall #1761

Revenue Y/Y Growth Statistics
High Average Low
29.57 % 9.54 % -0.6 %
(Jun 30 2021)   (Sep 30 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #278
Overall #1761
Revenue Y/Y Growth Statistics
High Average Low
29.57 % 9.54 % -0.6 %
(Jun 30 2021)   (Sep 30 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Idexx Laboratories Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13.21 % 2.39 % -8.23 %
(Sep 30 2020)  


IDXX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Idexx Laboratories Inc disclosed decrease in Revenue from the second quarter by -0.19% to $ 1,214.24 millions, from $ 1,216.59 millions achived in the previous reporting period.

But that's not important problem, as Idexx Laboratories Inc's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Idexx Laboratories Inc's Revenue growth quarter on quarter, overall rank is 994.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #994
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #994
Revenue Q/Q Growth Statistics
High Average Low
13.21 % 2.39 % -8.23 %
(Sep 30 2020)  


IDXX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Idexx Laboratories Inc disclosed decrease in Revenue from the second quarter by -0.19% to $ 1,214.24 millions, from $ 1,216.59 millions achived in the previous reporting period.

But that's not important problem, as Idexx Laboratories Inc's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Idexx Laboratories Inc's Revenue growth quarter on quarter, overall rank is 994.


Idexx Laboratories Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 4,663.68
Y / Y Revenue Growth (TTM) 11.94 %
Year on Year Revenue Growth Overall Ranking # 1839
Seqeuential Revenue Change (TTM) 2.41 %
Seq. Revenue Growth (TTM) Overall Ranking # 2352


Cumulative Revenue growth Comment
Assuming the Idexx Laboratories Inc's fiscal year would have ended in Sep 30 2026, Idexx Laboratories Inc would have reprted above average annual Revenue increase of 11.94% year on year, of $ 4,664 millions.
This marks a slow-down of the companys growth trends and from the 12.81% rise in Jun 30 2026.

In the Healthcare sector 288 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1253 to 1839.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 289
Overall # 1839

Revenue TTM Y/Y Growth Statistics
High Average Low
23.11 %
 9.78 %
4.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 338
S&P 500 # 2352
Cumulative Revenue growth Comment
Assuming the Idexx Laboratories Inc's fiscal year would have ended in Sep 30 2026, Idexx Laboratories Inc would have reprted above average annual Revenue increase of 11.94% year on year, of $ 4,664 millions.
This marks a slow-down of the companys growth trends and from the 12.81% rise in Jun 30 2026.

In the Healthcare sector 288 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1253 to 1839.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 6
Healthcare Sector # 289
Overall # 1839

Revenue TTM Y/Y Growth Statistics
High Average Low
23.11 %
9.78 %
4.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 338
S&P 500 # 2352




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IDXX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions


About Idexx Laboratories Inc Revenue Growth Rates (IDXX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Idexx Laboratories Inc (CIK 874716).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000874716-26-000135
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Idexx Laboratories Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.